Warby Parker Inc.
WRBYAbout the company
Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
3 / 12
NEUTRAL / FAIL
Median fair value
$0.81
-97.0% vs price
Models with upside
0 / 17
Positive margin of safety
Key risk
All 13 investors flag WRBY's valuation
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #1881 (Top 60.7%) | NEUTRAL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||
| Margin of Safety | -3287.7% | -17050.0% | N/A | N/A | N/A | N/A | -373.9% | -8475.0% | N/A | N/A | -153.4% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-26 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-26 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-26 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-26 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-26 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-02-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-26 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✗ 28▾
All 13 investors flag WRBY's valuation
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio9.3x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)P/E 2744.0x (growth N/A)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-0.2%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-0.2%, ROC=-5.2%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS2744.0x✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)31.0x✗Dreman< 8xPrice / Book Value per Share9.3x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessP/E=2744.0x, OE Yield=-0.4%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldP/E=2744.0x, FCF Yield=1.3%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/E=2744.0x, P/B=9.3x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share78.5x✗Ackman<= 25Price vs. Trailing Low166% of trailing low ($16.51)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization+0.22%; #3133/6340 (top 49.4%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.1182; #4648/6449 (top 72.1%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS2744.0x✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share9.33x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.2740; #3448/5247 (top 65.7%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization+0.62%; #2446/4519 (top 54.1%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+31.80%; #979/6202 (top 15.8%)✗OshaughnessyTop 10% of eligible cross-section - Valuation models0% pass✗ 5▾
WRBY overvalued: all 5 models price fair value below $27.44 (median $0.81)
Graham fair value$0.81✗Graham-3287.7% margin vs $27.44Buffett fair value$0.16✗Buffett-17050.0% margin vs $27.44Munger fair value$5.79✗Munger-373.9% margin vs $27.44Pabrai fair value$0.32✗Pabrai-8475.0% margin vs $27.44Ackman fair value$10.83✗Ackman-153.4% margin vs $27.44 - Profitability6% pass✓ 8✗ 27▾
15 of 16 flag WRBY's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)1/8 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)1/8 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-23.1%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-0.6% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$1.6M✓BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)P/E 2744.0x (growth N/A)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE1.9%✗Lynch> 15%EBIT / Enterprise Value-0.2%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-0.2%, ROC=-5.2%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets0.23%✓PiotroskiROA > 0ROA Change YoY-3.01% -> 0.23% (delta: +3.24%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=15.37%, ROA=0.23%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY55.3% -> 54.0%✗PiotroskiImproved YoYPre-Tax Income / Revenue1.1%✗Dreman>= 8%Net Income / Shareholders' Equity1.9%✗Dreman> 12%Margin of SafetyP/E=2744.0x, P/B=9.3x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-8.8% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency1/7 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue0.2%✗Ackman>= 15%Net Income / Shareholders Equity1.9%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-10.7% (2023) -> -0.6% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 54.5% -> 54.0%, operating margin -10.7% -> -0.6%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization+0.22%; #3133/6340 (top 49.4%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+64.60%; #406/3702 (top 11.0%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity+1.85%; #2772/5226 (top 53.0%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.1191; #3691/5884 (top 62.7%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years1/7 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts7% pass✓ 1✗ 13▾
Split decision: 12 FAIL · 3 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (2/9)✗LynchFAIL (1/7)✗GreenblattRank #1881•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag WRBY's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities2.26✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-16.4x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Growth13% pass✓ 4✗ 9▾
7 of 8 flag WRBY's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)P/E 2744.0x (growth N/A)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 1.5% vs Rev: 9.9%✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency1/7 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth13.0%✓Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 54.5% -> 54.0%, operating margin -10.7% -> -0.6%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR17.2%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag WRBY's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio2.26✓Graham>= 2.0ROIC (3-5 yr avg)✗Buffett> 10%ROIC - WACC✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-5.2%✗Greenblatt> 25%Current Ratio Change YoY2.50 -> 2.35✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY1.14x -> 1.21x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities2.26✓Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years - Cash Flow50% pass✓ 6✗ 6▾
5 of 10 pass — Lynch, Dreman, Pabrai +2 more object
Free Cash Flow Proxy$1.6M✓BuffettPositive and growingFCF Positive and Growing$21.3M✗LynchPositive and growingOperating Cash Flow$110.8M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=15.37%, ROA=0.23%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)31.0x✗Dreman< 8xP/E or FCF YieldP/E=2744.0x, FCF Yield=1.3%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive4/7 years FCF positive✓MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap0.6%✗Ackman>= 4%Price / FCF per Share78.5x✗Ackman<= 25Positive Operating Cash Flow frequency6/7 years positive✓SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$21.3M✓Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization+0.62%; #2446/4519 (top 54.1%)✗OshaughnessyTop 10% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 3.9% of shares last year, 6.6% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.4Bcurrent | -- | -- | -- | $3.2Best. | $3.3Best. | $1.5Best. | $1.9Best. | $2.6Best. |
| Revenue | $934.7M↑10% | $244.7M↑10% | $235.5M↑10% | $242.4M↑8% | $871.9M↑13% | $771.3M↑15% | $669.8M↑12% | $598.1M↑11% | $540.8M |
| Operating Income | $1.5M↑119% | $3.6M | $3.2M↑170% | $1.7M↓33% | -$5.3M↑82% | -$30.1M↑58% | -$72.0M↑35% | -$111.2M↑23% | -$143.7M |
| Net Income | $7.5M↑942% | $5.6M↓5% | $4.6M↑365% | $3.2M↓8% | $1.6M↑108% | -$20.4M↑68% | -$63.2M↑43% | -$110.4M↑23% | -$144.3M |
| EPS (Diluted) | -- | $0.04↓20% | $0.04↑500% | $0.03 | $0.01↑106% | $-0.17↑69% | $-0.54↑44% | $-0.96↑57% | $-2.21 |
| Gross Margin | 54.7%↑1% | 54.4%↑1% | 57.9%↑9% | 54.0%↓4% | 54.0%↓2% | 55.3%↑1% | 54.5%↓4% | 57.0%↓3% | 58.8% |
| Operating Margin | 0.2%↑118% | 1.5%↓10% | 1.3%↑164% | 0.7%↓38% | -0.6%↑84% | -3.9%↑64% | -10.7%↑42% | -18.6%↑30% | -26.6% |
| ROE | 1.9%↑855% | — | — | — | 0.4%↑107% | -6.0%↑71% | -20.9%↑46% | -38.5%↑24% | -50.4% |
| Total Debt | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Shareholders' Equity | $403.3M↑9% | $403.3M↑9% | $392.0M↑8% | $375.8M↑6% | $367.7M↑8% | $340.1M↑13% | $301.8M↑5% | $286.6M | $286.0M |
| Current Ratio | 2.26↓13% | 2.26↓13% | 2.27↓11% | 2.33↓13% | 2.35↓6% | 2.50↑6% | 2.35↑3% | 2.27↓18% | 2.78 |
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| Operating Cash Flow | $102.1M↓5% | $24.7M↑38% | $29.6M↓26% | $24.5M↓17% | $110.8M↑12% | $98.7M↑62% | $61.0M↑488% | $10.4M↑132% | -$32.0M |
| Free Cash Flow | $21.3M↓44% | -$2.0M↓30% | $6.8M↓72% | $8.4M↓37% | $43.7M↑26% | $34.7M↑374% | $7.3M↑115% | -$49.8M↑38% | -$80.5M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
WRBY vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |